AZD8529

Ligand id: 7678

Name: AZD8529

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 83.73
Molecular weight 487.18
XLogP 3.91
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Main indication was for treatment of schizophrenia (see for example, clinical trial NCT00921804, or click here for a full listing of ClinicalTrials.gov registered AZD8529 trials). It failed to reach its clinical endpoint in Phase II clinical trials, and development was halted.
Mechanism Of Action and Pharmacodynamic Effects
AZD8529 is a positive allosteric modulator (PAM) of the presynaptic autoreceptor metabotropic glutamate receptor 2 (mGluR2). The rationale for mGluR2 as a target for schizophrenia was based on the hypothesis that failure of cortical glutamatergic drive results in disinhibition of subcortical dopamine function, which in turn leads to psychosis. Activation of mGluR2 is proposed to effect a normalization of glutamatergic function which should have antipsychotic effects.